"Introducing Filsuvez is a promising start, as it can offer temporary pain relief, and we hope it will mark the beginning for the treatment of EB in Ireland."
"This decision represents hope, dignity and meaningful progress for EB patients and their families. For too long, people living with EB have had no approved treatment options."
"Ireland is in the lowest quartile in Europe for introducing new drugs to the market. The average timeline from European Medicines Agency decision to reimbursement in this country is 1,024 days."
Filsuvez, a new gel treatment for epidermolysis bullosa (EB), will be available to patients in Ireland, easing the lives of 300 individuals with this condition. The gel promotes healing of wounds and reduces pain, applied directly to the skin or on dressings. The HSE will cover most costs for eligible patients. Debra's chief executive emphasized this as a transformative moment, representing hope and progress for EB patients, who have long lacked approved treatment options. Ireland's slow drug approval process has hindered access to new treatments.
Read at Irish Independent
Unable to calculate read time
Collection
[
|
...
]